Pharmaceuticals news and information

Abbott Laboratories reported higher-than-expected quarterly earnings on Wednesday, helped by strong demand for its diagnostics, and surprised investors with a dividend increase of more than 50%.
FULL STORY »

Where seniors live makes a difference not only in how much healthcare they receive but also the medications they're prescribed—as some miss out on key treatments while others get risky ones.
FULL STORY »

Johnson & Johnson reported better-than-expected third-quarter results, as strong growth for prescription drugs overshadowed weaker contributions from its medical device and consumer products businesses.
FULL STORY »

Some major health insurers have reduced patient cost-sharing for preventive drugs out of a growing realization that lowering cost-sharing improves compliance and cuts the total cost of care.
FULL STORY »

Drugmaker Fresenius Kabi confirmed on Thursday that it took the extraordinary step of suspending shipments of a widely used drug to a U.S. distributor this year after 20 vials were mistakenly sent to the state of Missouri to be used in executions.
FULL STORY »

Teva Pharmaceutical Industries, the world's largest maker of generic drugs, plans to eliminate about 5,000 jobs as it accelerates cost reductions amid growing competition for the company's best-selling product.
FULL STORY »

The hunt for cheaper prescription drugs long has led consumers to reach beyond U.S. borders, but under a Maine law set to take effect Wednesday, their search now will have the state's blessing.
FULL STORY »

Months after the latest trial of a possible HIV vaccine were halted because it was ineffective, newly published details suggest researchers and advocates made important strides with some the country's hardest-hit and difficult-to-reach populations.
FULL STORY »

One of the victims of last year's deadly outbreak of fungal meningitis has suffered a relapse.Rebecca Climer, spokeswoman for Nashville's St. Thomas West Hospital, wrote in an e-mail that a patient was admitted after suffering a reoccurrence of the sometimes-deadly infection.
FULL STORY »

The market for drug therapies for rare diseases is becoming increasingly crowded with expensive new products, a Modern Healthcare review of FDA approval and company pricing data shows.
FULL STORY »